• bioAffinity Technologies received a Nasdaq staff determination for failing the $1 minimum bid price rule, with shares below $1 for 30 sessions.
• Nasdaq denied the standard 180-day cure period because of a 1-for-30 reverse split on Sept. 19, 2025.
• An appeal due Aug. 6, 2026 would stay delisting pending a Nasdaq hearings panel decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035672), on July 31, 2026, and is solely responsible for the information contained therein.